New oral drug trial offers hope for Tough-to-Treat cancers
NCT ID NCT05988918
Summary
This study is testing whether an oral medication called ESK981 can help control advanced pancreatic cancers and neuroendocrine tumors that have stopped responding to standard treatments. The trial will enroll 66 patients who will take the drug capsules on a 5-days-on, 2-days-off schedule. Researchers will track whether the treatment slows cancer growth and extends survival time for participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbara Ann Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
Contact
-
Rogel Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-••••
Contact
-
University of Wisconsin Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.